Drugs / V3-X
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03042182 | Feb 2017 → Feb 2020 | cholangiocarcinoma | Immunitor LLC | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V3-X | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03042182 ↗ |
| Modality | Vaccine | “oral therapeutic vaccine V3-X” NCT03042182 ↗ |
| Route | Oral | “One pill of oral therapeutic vaccine V3-X administered to patients with cholangiocarcinoma for two months” NCT03042182 ↗ |